Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy.

Saved in:
Bibliographic Details
Title: Association of integrated biomarkers and progression-free survival prediction in patients with gastroenteropancreatic neuroendocrine tumors undergoing [177Lu]Lu-DOTA-TATE therapy.
Authors: Herr FL; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Dascalescu C; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Ebner R; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Schnitzer ML; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Fabritius MP; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Schmid-Tannwald C; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Zacherl MJ; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany., Wenter V; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany., Unterrainer LM; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.; Bayerisches Zentrum für Krebsforschung (BZKF), partner site Munich, Germany., Brendel M; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.; DZNE - German Center for Neurodegenerative Diseases, Munich, Germany.; Munich Cluster for Systems Neurology (SyNergy), University of Munich, Munich, Germany.; German Cancer Consortium (DKTK), partner site Munich, a partnership between DKFZ and LMU, Germany., Holzgreve A; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany., Werner RA; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany.; The Russell H. Morgan Department of Radiology and Radiological Sciences, Division of Nuclear Medicine and Molecular Imaging, Johns Hopkins University School of Medicine, Baltimore, Maryland., Auernhammer CJ; Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS certified Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.; Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany., Spitzweg C; Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS certified Center of Excellence), LMU University Hospital, LMU Munich, Munich, Germany.; Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany., Knösel T; Department of Pathology, LMU University Hospital, LMU Munich, Munich, Germany., Burkard T; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Ricke J; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Heimer MM; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany., Sheikh GT; Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Germany., Cyran CC; Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
Source: Theranostics [Theranostics] 2025 May 25; Vol. 15 (13), pp. 6444-6453. Date of Electronic Publication: 2025 May 25 (Print Publication: 2025).
Publication Type: Journal Article
Journal Info: Publisher: Ivyspring International Publisher Country of Publication: Australia NLM ID: 101552395 Publication Model: eCollection Cited Medium: Internet ISSN: 1838-7640 (Electronic) Linking ISSN: 18387640 NLM ISO Abbreviation: Theranostics Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1838-7640
DOI:10.7150/thno.112588